27 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
large B-cell lymphoma (“DLBCL”), mantle cell lymphoma (“MCL”), follicular lymphoma (“FL”), and chronic lymphocytic leukemia (“CLL”).
Furthermore, obe
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
11 Dec 23
Regulation FD Disclosure
8:31am
blasts without EMD) as measured at screening and lymphodepletion B-ALL, B-cell acute lymphoblastic leukemia; B-CLL, B-cell chronic lymphocytic leukemia … lymphoblastic leukemia; B-CLL, B-cell chronic lymphocytic leukemia; B-NHL, B-cell non-Hodgkin lymphoma; CAR, chimeric antigen receptor; obe-cel
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
11 Dec 23
Regulation FD Disclosure
8:31am
), and a Phase Ib/II study (FELIX). Additionally, obe-cel has been tested in patients with R/R B-cell chronic lymphocytic leukemia (B-CLL) and R/R B-cell
6-K
EX-99.2
AUTL
Autolus Therapeutics plc
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
), mantle cell lymphoma (MCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Patients continue to be enrolled into the study and we
6-K
EX-99.3
AUTL
Autolus Therapeutics plc
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Patients continue
6-K
EX-99.3
7o6ch4p2
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-99.2
qk2d4q
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
424B5
xnb5q0
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
4pdpxv 0oyw3tc1iftl
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K
EX-99.2
eq31gybkz28uwvt
4 Aug 22
Index to Condensed Consolidated Financial Statements
4:06pm
6-K
EX-99.3
pc5jv1b71po
4 Aug 22
Index to Condensed Consolidated Financial Statements
4:06pm
424B5
1t5wsdkbge7ex86tfy
19 Aug 21
Prospectus supplement for primary offering
4:13pm
F-3
ri61lgtsia 4yz8do0
6 Aug 21
Shelf registration (foreign)
2:30pm
6-K
EX-1
p9mxrn11ywq n17b
30 Jun 21
Annual Report and Accounts
6:05am
424B5
35e2pvkpvzg0et
11 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
9bw0k
8 Feb 21
Prospectus supplement for primary offering
5:27pm
6-K
EX-99.1
prmcns9
7 Dec 20
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL
4:00pm
6-K
EX-1
vtck2kq3k
26 May 20
Current report (foreign)
4:31pm